GoodRx expects to report one or more material weaknesses in financial controls
GDRX•GoodRx expects to report one or more material weaknesses in internal control over financial reporting and filed its 10-Q late; it plans to release third-quarter results and file the report within a five-calendar-day extension period.
1. Filing delay
GoodRx said it currently expects to report one or more material weaknesses in internal control over financial reporting and has filed a non-timely 10-Q with the SEC. The company plans to release its third-quarter results and file the 10-Q promptly within a five-calendar-day extension period.
